Posts by: Joana Carvalho

Joana Carvalho

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.

January 21, 2021January 21, 2021

Zejula Now Available in UK as Maintenance Therapy for Advanced Ovarian Cancer

News

The National Institute of Health and Care Excellence (NICE) has recommended the use of Zejula (niraparib) as a maintenance therapy for people with advanced ovarian, fallopian tube, or primary ... Read more

January 5, 2021January 5, 2021

Trial Confirms Rubraca’s Clinical Benefit Over Chemotherapy

News

Rubraca (rucaparib) is superior to chemotherapy at prolonging life without disease worsening in people with advanced ovarian cancer who received at least two prior lines of chemotherapy, according to top-line ... Read more

December 17, 2020December 17, 2020

STRO-002 Continues to Show Promise in Phase 1 Trial for Advanced Ovarian Cancer

News

STRO-002, Sutro Biopharma’s experimental antibody-drug conjugate, continues to be safe and elicit promising responses in heavily pretreated patients with advanced ovarian cancer, according to the latest data from a ... Read more

December 10, 2020December 10, 2020

Anixa Enters License Agreement With Cleveland Clinic for Ovarian Cancer Vaccine

News

Anixa Biosciences has entered in a license agreement with the Cleveland Clinic to obtain the exclusive, global rights for a new ovarian cancer vaccine technology. “Through this collaboration we are ... Read more

December 1, 2020December 1, 2020

Assisted Reproductive Technology Does Not Raise Risk of Ovarian Cancer, Study Indicates

News

Women who use assisted reproductive technology to help them conceive a child appear not to be at an increased risk of developing ovarian cancer, a nationwide study conducted in ... Read more

November 24, 2020November 24, 2020

ALKS 4230-Keytruda Combo Found to Reduce Tumor Size, Halt Disease Progression

News

The combination of Keytruda (pembrolizumab) and ALKS 4230 was able to halt disease progression and reduce tumor size in a small group of heavily pre-treated patients with advanced ovarian ... Read more

November 3, 2020November 3, 2020

Zejula Approved in Europe as Maintenance Therapy for Advanced Ovarian Cancers

News

The European Commission has approved Zejula (niraparib) as a first-line maintenance therapy for people with advanced ovarian, fallopian tube, or primary peritoneal cancer, who respond to platinum-based chemotherapy. This ... Read more

September 22, 2020September 22, 2020

CHMP Favors Zejula as First-line Maintenance Therapy for Platinum-sensitive Advanced Ovarian Cancer

News

The Committee for Medicinal Products for Human Use (CHMP) has recommended Zejula (niraparib) as a first-line maintenance therapy for women with advanced ovarian cancer who responded to platinum-based chemotherapy. This favorable ... Read more

September 3, 2020September 3, 2020

Research Alliance Hopes to Raise $200K During Awareness Month

News

The Ovarian Cancer Research Alliance (OCRA) is hoping to raise $200,000 in this year’s awareness month campaign to help fund research and support those with the disease, the organization ... Read more

August 13, 2020August 13, 2020

XMT-1536 on FDA Fast Track for Platinum-resistant, Advanced Ovarian Cancer

News

The U.S. Food and Drug Administration (FDA) has given fast track designation to Mersana Therapeutics’ XMT-1536 as a possible treatment for women with platinum-resistant high-grade serous ovarian cancer who received up to three prior ... Read more